GlassScriptPhysician profile
Jordan Jamerson
NPI 1285012153
$1,787.30
in general payments reported to CMS, 2019-2025
17 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $17.52 · 2021: $13.47 · 2022: $39.52 · 2023: $244 · 2024: $398 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.04 |
| Education | $215.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $373.86 | 2019-2025 | |
| Abbvie INC. | $294.45 | 2019-2025 | |
| Janssen Biotech, INC. | $282.82 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $133.54 | 2019-2023 | |
| Merz North America, INC. | $130.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $96.17 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $81.74 | 2023-2024 | Dupixent |
| Ucb, INC. | $63.05 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $61.91 | 2025 | Zoryve |
| Genzyme Corporation | $55.96 | 2023-2024 | |
| Amgen INC. | $45.59 | 2024-2025 | Otezla, Otezla |
| Krystal Biotech INC | $43.86 | 2024 | Vyjuvek |
| Dermavant Sciences, INC. | $34.94 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $29.93 | 2025 | Nemluvio |
| Incyte Corporation | $24.65 | 2024 | Opzelura |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $21.73 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Advanced Oxygen Therapy INC. | $12.94 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Jamerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.